Early human development · 2025
In utero lead exposure and auditory neural myelination in premature infants.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amin Radhika S, Orlando Mark S, Amin Sanjiv B
Аннотация
BACKGROUND: In studies of term infants, in-utero low level lead exposure was associated with developmental neurotoxicity, including abnormal auditory neural myelination (ANM). However, this association has not been well-studied in premature infants who may be more susceptible to lead associated developmental neurotoxicity.
AIM: To evaluate if low level in-utero lead exposure is associated with developmental neurotoxicity as evaluated by ANM in premature infants.
METHODS: A prospective observational study was performed in singleton infants 24-33 weeks gestational age (GA). Cord blood lead level was measured using Inductively Coupled Plasma Mass Spectrometry. Auditory brainstem evoked response (ABR) was performed in each ear at 35 weeks post-menstrual age (PMA) to evaluate inter-peak latencies (IPL), a measure of ANM.
RESULTS: A total of 103 infants were studied. The mean (standard deviation) GA was 29.3 (1.8) weeks. The mean (range) cord blood lead level was 0.54 (0.065-5.30) ug/dL. On multiple linear regression analyses, controlling for confounders, cord lead levels were not associated (p > 0.05) with right ear IPLs (beta coefficients, 95 % confidence intervals): I-III (-0.001, -0.014-0.012), III-V (0.005, -0.007-0.018), or I-V (0.002, -0.015-0.020). There was also no association (p > 0.05) with left ear IPLs: I-III (-0.002, -0.017-0.012), III-V (-0.003, -0.015-0.008), or I-V (-0.006, -0.026-0.013).
CONCLUSION: Our findings suggest that in-utero low level lead exposure of ≤5.30 μg/dL is not associated with adverse effects on ANM when evaluated at 35 weeks PMA in infants ≤33 weeks GA.
AIM: To evaluate if low level in-utero lead exposure is associated with developmental neurotoxicity as evaluated by ANM in premature infants.
METHODS: A prospective observational study was performed in singleton infants 24-33 weeks gestational age (GA). Cord blood lead level was measured using Inductively Coupled Plasma Mass Spectrometry. Auditory brainstem evoked response (ABR) was performed in each ear at 35 weeks post-menstrual age (PMA) to evaluate inter-peak latencies (IPL), a measure of ANM.
RESULTS: A total of 103 infants were studied. The mean (standard deviation) GA was 29.3 (1.8) weeks. The mean (range) cord blood lead level was 0.54 (0.065-5.30) ug/dL. On multiple linear regression analyses, controlling for confounders, cord lead levels were not associated (p > 0.05) with right ear IPLs (beta coefficients, 95 % confidence intervals): I-III (-0.001, -0.014-0.012), III-V (0.005, -0.007-0.018), or I-V (0.002, -0.015-0.020). There was also no association (p > 0.05) with left ear IPLs: I-III (-0.002, -0.017-0.012), III-V (-0.003, -0.015-0.008), or I-V (-0.006, -0.026-0.013).
CONCLUSION: Our findings suggest that in-utero low level lead exposure of ≤5.30 μg/dL is not associated with adverse effects on ANM when evaluated at 35 weeks PMA in infants ≤33 weeks GA.